Diagnostic microbiology and infectious disease · 2024
Unlocking the potential of dried blood spot sampling for SARS-CoV-2 antibody detection: A pathway to efficient pandemic surveillance.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alharbi Ahmad M
Аннотация
UNLABELLED: The current SARS-CoV-2 pandemic has exerted unprecedented pressure on global healthcare systems, with an urgent demand for widespread testing to monitor virus spread and contribute to disease control.
AIM: This study aimed to validate the use of Dried Blood Spot (DBS) sampling for analyzing the immune response to SARS-CoV-2 infection, employing an accessible enzyme-linked immunosorbent assay (ELISA) for detecting IgG antibodies.
METHODOLOGY: Traditional venous blood sampling presents several challenges, including discomfort to patients, risk of healthcare provider exposure, and the need for specialized equipment, which can limit mass testing capabilities. Our research involved the comparison of DBS and venous blood samples from 170 individuals, all of whom had PCR-confirmed SARS-CoV-2 infection, to assess the efficacy of DBS for seroprevalence studies and vaccine response evaluation.
RESULTS: Our results confirmed that DBS sampling could detect SARS-CoV-2 IgG antibodies with 100 % accuracy, showcasing perfect agreement (Cohen's k value of 1.00) between DBS and venous serum samples in detecting the viral antibodies. However, the analysis indicated no significant correlation between the antibody levels in the two sampling methods.
CONCLUSION: These results suggest that DBS is a viable, rapid alternative for serological studies, offering a solution to current testing limitations and enhancing our public health approach to combating future pandemics.
AIM: This study aimed to validate the use of Dried Blood Spot (DBS) sampling for analyzing the immune response to SARS-CoV-2 infection, employing an accessible enzyme-linked immunosorbent assay (ELISA) for detecting IgG antibodies.
METHODOLOGY: Traditional venous blood sampling presents several challenges, including discomfort to patients, risk of healthcare provider exposure, and the need for specialized equipment, which can limit mass testing capabilities. Our research involved the comparison of DBS and venous blood samples from 170 individuals, all of whom had PCR-confirmed SARS-CoV-2 infection, to assess the efficacy of DBS for seroprevalence studies and vaccine response evaluation.
RESULTS: Our results confirmed that DBS sampling could detect SARS-CoV-2 IgG antibodies with 100 % accuracy, showcasing perfect agreement (Cohen's k value of 1.00) between DBS and venous serum samples in detecting the viral antibodies. However, the analysis indicated no significant correlation between the antibody levels in the two sampling methods.
CONCLUSION: These results suggest that DBS is a viable, rapid alternative for serological studies, offering a solution to current testing limitations and enhancing our public health approach to combating future pandemics.